HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $3.31 million. The enterprise value is $2.16 million.
Important Dates
The next estimated earnings date is Thursday, March 13, 2025, after market close.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 980,321 shares outstanding. The number of shares has increased by 637.06% in one year.
| Current Share Class | 980,321 |
| Shares Outstanding | 980,321 |
| Shares Change (YoY) | +637.06% |
| Shares Change (QoQ) | +17.96% |
| Owned by Insiders (%) | 8.69% |
| Owned by Institutions (%) | 7.24% |
| Float | 895,115 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 166.06 |
| Forward PS | n/a |
| PB Ratio | 0.80 |
| P/TBV Ratio | 1.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 146.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.72 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.71 |
Financial Efficiency
Return on equity (ROE) is -644.23% and return on invested capital (ROIC) is -128.39%.
| Return on Equity (ROE) | -644.23% |
| Return on Assets (ROA) | -91.98% |
| Return on Invested Capital (ROIC) | -128.39% |
| Return on Capital Employed (ROCE) | -166.85% |
| Revenue Per Employee | $980 |
| Profits Per Employee | -$508,305 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.60% in the last 52 weeks. The beta is 2.90, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.90 |
| 52-Week Price Change | -74.60% |
| 50-Day Moving Average | 3.49 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 48.62 |
| Average Volume (20 Days) | 15,154 |
Short Selling Information
The latest short interest is 38,452, so 3.92% of the outstanding shares have been sold short.
| Short Interest | 38,452 |
| Short Previous Month | 31,207 |
| Short % of Shares Out | 3.92% |
| Short % of Float | 4.30% |
| Short Ratio (days to cover) | 2.41 |
Income Statement
In the last 12 months, HeartSciences had revenue of $14,700 and -$7.62 million in losses. Loss per share was -$10.54.
| Revenue | 14,700 |
| Gross Profit | 10,139 |
| Operating Income | -7.47M |
| Pretax Income | -6.61M |
| Net Income | -7.62M |
| EBITDA | -7.43M |
| EBIT | -7.47M |
| Loss Per Share | -$10.54 |
Full Income StatementBalance Sheet
The company has $4.05 million in cash and $2.90 million in debt, giving a net cash position of $1.15 million or $1.17 per share.
| Cash & Cash Equivalents | 4.05M |
| Total Debt | 2.90M |
| Net Cash | 1.15M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 4.02M |
| Book Value Per Share | 4.24 |
| Working Capital | 2.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.88 million and capital expenditures -$60,750, giving a free cash flow of -$7.94 million.
| Operating Cash Flow | -7.88M |
| Capital Expenditures | -60,750 |
| Free Cash Flow | -7.94M |
| FCF Per Share | -$8.10 |
Full Cash Flow StatementMargins
| Gross Margin | 68.97% |
| Operating Margin | -50,788.24% |
| Pretax Margin | -51,867.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -637.06% |
| Shareholder Yield | -637.06% |
| Earnings Yield | -230.44% |
| FCF Yield | -240.00% |
Analyst Forecast
The average price target for HeartSciences is $13.50, which is 299.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.50 |
| Price Target Difference | 299.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
HeartSciences has an Altman Z-Score of -14.77 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.77 |
| Piotroski F-Score | 3 |